
Gowthami M Arepally

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7418383/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO. Molecular Therapy - Nucleic Acids, 2022, 27, 524-534.	2.3	5
2	The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	4
3	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney International Reports, 2021, 6, 1603-1613.	0.4	29
4	Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood, 2021, 138, 293-298.	0.6	87
5	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. Blood, 2021, 138, 2106-2116.	0.6	23
6	Thrombocytopenia and splanchnic thrombosis after Ad26. <scp>COV2</scp> .S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy. American Journal of Hematology, 2021, 96, 1180-1182.	2.0	13
7	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
8	COVID-19 and VITT: same or different?. Blood, 2021, 138, 1206-1207.	0.6	1
9	Fc-Modified Kko: A Novel Therapeutic for Heparin-Induced Thrombocytopenia (HIT), Reversing Both the Thrombocytopenia and Thrombosis. Blood, 2021, 138, 581-581.	0.6	1
10	Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications. Blood, 2021, 138, 292-292.	0.6	5
11	Neutrophil Phenotypes Result in Differential Responses to Pathogens. Blood, 2021, 138, 988-988.	0.6	0
12	Minimal Role for the Alternative Pathway in Complement Activation By HIT Immune Complexes. Blood, 2021, 138, 2076-2076.	0.6	0
13	Heparin-Induced Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 141-152.	1.1	37
14	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naÃ ⁻ ve to complement inhibitor treatment. Kidney International, 2020, 97, 1287-1296.	2.6	123
15	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962092909.	0.7	26
16	Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood, 2020, 135, 1270-1280.	0.6	55
17	Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis. Blood, 2020, 135, 743-754.	0.6	39
18	Pathogenesis of heparin-induced thrombocytopenia. Translational Research, 2020, 225, 131-140.	2.2	61

GOWTHAMI M AREPALLY

#	Article	IF	CITATIONS
19	Variation in Neutrophil Function Among Healthy Subjects Influences Response to Bacteria. Blood, 2020, 136, 34-34.	0.6	0
20	Complement Regulates the Procoagulant Effects of HIT Immune Complexes. Blood, 2020, 136, 11-12.	0.6	0
21	The risk of major bleeding in patients with suspected heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 1956-1965.	1.9	42
22	Heterogeneity in neutrophil responses to immune complexes. Blood Advances, 2019, 3, 2778-2789.	2.5	10
23	Plastic-based acoustofluidic devices for high-throughput, biocompatible platelet separation. Lab on A Chip, 2019, 19, 394-402.	3.1	34
24	Bad weed: synthetic cannabinoid–associated coagulopathy. Blood, 2019, 133, 902-905.	0.6	19
25	Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis. Blood, 2019, 134, 10-10.	0.6	Ο
26	Transfusion-Dependent Anemia and Coagulopathy in a Porcine Model of Pediatric Extracorporeal Membrane Oxygenation (ECMO). Blood, 2019, 134, 1164-1164.	0.6	0
27	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. Journal of Clinical Apheresis, 2018, 33, 469-479.	0.7	2
28	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	2.5	448
29	Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight, 2018, 3, .	2.3	115
30	Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. Blood, 2018, 132, 2431-2440.	0.6	35
31	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3155-3162.	2.5	38
32	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. Thrombosis and Haemostasis, 2018, 118, 1484-1487.	1.8	7
33	Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT). Autoimmunity Reviews, 2018, 17, 1046-1052.	2.5	11
34	Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology, 2018, 36, 606-613.	9.4	52
35	Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. Blood, 2018, 132, 727-734.	0.6	9
36	Antibody Stabilization of Neutrophil Extracellular Trap-Platelet Factor 4 Complexes Is Therapeutic in a Murine Model of Endotoxemia. Blood, 2018, 132, 271-271.	0.6	0

#	Article	IF	CITATIONS
37	Etiology and complications of thrombocytopenia in hospitalized medical patients. Journal of Thrombosis and Thrombolysis, 2017, 43, 429-436.	1.0	17
38	Heparin-induced thrombocytopenia. Blood, 2017, 129, 2864-2872.	0.6	319
39	PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. Thrombosis Research, 2017, 159, 39-47.	0.8	14
40	Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner. Therapeutic Apheresis and Dialysis, 2017, 21, 441-450.	0.4	10
41	Novel therapeutic approaches for thrombotic thrombocytopenic purpura. Current Opinion in Hematology, 2017, 24, 521-528.	1.2	4
42	Thrombocytopenia in hospitalized patients with severe clostridium difficile infection. Journal of Thrombosis and Thrombolysis, 2017, 43, 38-42.	1.0	9
43	Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies. Blood Advances, 2017, 1, 644-651.	2.5	9
44	Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. Journal of Clinical Investigation, 2017, 127, 1090-1098.	3.9	37
45	Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. Blood Advances, 2016, 1, 62-74.	2.5	58
46	lmmune pathogenesis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 792-798.	1.8	31
47	Heparin-induced thrombocytopenia: research and clinical updates. Hematology American Society of Hematology Education Program, 2016, 2016, 262-268.	0.9	14
48	The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21). Blood, 2016, 128, 1789-1799.	0.6	45
49	The thrombotic microangiopathy Registry of North America: A United States multiâ€institutional <scp>TMA</scp> network. Journal of Clinical Apheresis, 2016, 31, 448-453.	0.7	9
50	Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes. Blood, 2016, 128, 3734-3734.	0.6	0
51	RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit. Blood, 2016, 128, 3823-3823.	0.6	Ο
52	Mechanism of Complement Activation By PF4/ Heparin Complexes. Blood, 2016, 128, 137-137.	0.6	0
53	Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding. Biology of Blood and Marrow Transplantation, 2015, 21, S111-S113.	2.0	2
54	Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?. Annual Review of Medicine, 2015, 66, 241-253.	5.0	19

GOWTHAMI M AREPALLY

#	Article	IF	CITATIONS
55	Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nature Communications, 2015, 6, 8277.	5.8	101
56	Characterization of Human and Murine Anti-Protamine/Heparin Antibodies. Blood, 2015, 126, 3461-3461.	0.6	1
57	The Thrombotic Microangiopathy Registry of North America. Blood, 2015, 126, 5587-5587.	0.6	2
58	Thrombocytopenia in Hospitalized Non-ICU Patients. Blood, 2015, 126, 1060-1060.	0.6	0
59	Biologic Activities of Protamine/Heparin Antibodies. Blood, 2014, 124, 2784-2784.	0.6	9
60	Predicting the Temporal Course of Laboratory Abnormality Resolution in Patients with Thrombotic Microangiopathy. Blood, 2014, 124, 4192-4192.	0.6	3
61	Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT). Blood, 2014, 124, 465-465.	0.6	0
62	Understanding the Underlying Immune Response in HIT: Uptake of PF4/Heparin Complexes By Monocytes & Dendritic Cells. Blood, 2014, 124, 4197-4197.	0.6	0
63	Distinct Specificity and Single-molecule Kinetics Characterize the Interaction of Pathogenic and Non-pathogenic Antibodies against Platelet Factor 4-Heparin Complexes with Platelet Factor 4. Journal of Biological Chemistry, 2013, 288, 33060-33070.	1.6	24
64	High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood, 2013, 121, 2828-2835.	0.6	50
65	Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood, 2013, 121, 3484-3492.	0.6	49
66	Novel diagnostic assays for heparin-induced thrombocytopenia. Blood, 2013, 121, 3727-3732.	0.6	41
67	PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fcl³RI. Blood, 2012, 119, 5285-5293.	0.6	92
68	HIT and run: heparin's unusual immune response. Blood, 2012, 120, 4119-4120.	0.6	1
69	American society for apheresis white paper: Considerations for medical staff apheresis medicine physician credentialing and privileging. Journal of Clinical Apheresis, 2012, 27, 330-335.	0.7	10
70	Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thrombosis and Haemostasis, 2012, 107, 717-725.	1.8	27
71	Anticoagulation techniques in apheresis: From heparin to citrate and beyond. Journal of Clinical Apheresis, 2012, 27, 117-125.	0.7	136
72	Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 2012, 120, 267-267.	0.6	1

#	Article	IF	CITATIONS
73	Critical Role for Mouse Marginal Zone B Cells in PF4/Heparin Antibody Production. Blood, 2012, 120, 1175-1175.	0.6	18
74	High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass. Blood, 2012, 120, 3344-3344.	0.6	0
75	PF4/H Complexes Induce Germinal Centers in Vivo. Blood, 2012, 120, 269-269.	0.6	0
76	Novel Techniques for Measurement of Variable Sized PF4/H Complexes Blood, 2012, 120, 2204-2204.	0.6	0
77	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. Blood, 2011, 118, 1159-1159.	0.6	0
78	Comparative Analysis of von Willebrand Factor Profiles in Pulsatile and Continuous Left Ventricular Assist Device Recipients. ASAIO Journal, 2010, 56, 441-445.	0.9	92
79	Plasmapheresis and Heparin Reexposure as a Management Strategy for Cardiac Surgical Patients with Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2010, 110, 30-35.	1.1	103
80	Heparin modifies the immunogenicity of positively charged proteins. Blood, 2010, 116, 6046-6053.	0.6	49
81	Acquired von Willebrand Syndrome in Continuous-Flow Ventricular Assist Device Recipients. Annals of Thoracic Surgery, 2010, 90, 1263-1269.	0.7	338
82	Aprotinin Improves Functional Outcome but Not Cerebral Infarct Size in an Experimental Model of Stroke During Cardiopulmonary Bypass. Anesthesia and Analgesia, 2010, 111, 38-45.	1.1	8
83	The Use of Antithrombotic Therapies in the Prevention and Treatment of Arterial and Venous Thrombosis. Critical Pathways in Cardiology, 2010, 9, 41-48.	0.2	25
84	Heparin-Induced Thrombocytopenia. Annual Review of Medicine, 2010, 61, 77-90.	5.0	104
85	Platelet Factor 4/Heparin Antibodies in Blood Bank Donors. American Journal of Clinical Pathology, 2010, 134, 774-780.	0.4	72
86	Disruption of PF4/Hep Multimolecular Complex Assembly Using a Minimally Anticoagulant Heparin (ODSH). Blood, 2010, 116, 723-723.	0.6	0
87	Heparin Modifies the Immunogenicity of Positively-Charged Proteins Blood, 2010, 116, 1435-1435.	0.6	1
88	Dendritic Cell Activation by PF4/H Multimolecular Complexes. Blood, 2010, 116, 722-722.	0.6	0
89	Nothing typical about HIT. Blood, 2009, 113, 4825-4826.	0.6	2
90	Characterization of Receptors Involved in Heparin Antibody Complex Mediated Induction of Tissue Factor Expression in Monocytes Blood, 2009, 114, 224-224.	0.6	2

#	Article	IF	CITATIONS
91	Heparin Forms Macromolecular Complexes with Protamine and Lysozyme Blood, 2009, 114, 1316-1316.	0.6	Ο
92	Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. Journal of Thrombosis and Thrombolysis, 2008, 26, 55-61.	1.0	35
93	Response to Boctor and Smith. American Journal of Hematology, 2008, 83, 256-256.	2.0	2
94	Platelet factor 4â€heparin complexes trigger immune responses independently of the MyD88 pathway. British Journal of Haematology, 2008, 142, 671-673.	1.2	8
95	Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertility and Sterility, 2008, 90, 673-677.	0.5	48
96	Monocytes Are a Particularly Favorable Target for Surface Platelet Factor 4 (PF4) Antigenic Complex Formation in Heparin-Induced Thrombocytopenia: New Insights into the Thrombotic Risk in HIT. Blood, 2008, 112, 271-271.	0.6	1
97	Development of mPF4/Heparin Antibodies in a Murine Platelet Activation Model. Blood, 2008, 112, 270-270.	0.6	0
98	Seroprevalence of PF4/Heparin Antibodies among Blood Bank Donors. Blood, 2008, 112, 4536-4536.	0.6	0
99	Influence of Sample Collection and Storage on the Detection of Platelet Factor 4–Heparin Antibodies. American Journal of Clinical Pathology, 2007, 128, 150-155.	0.4	7
100	Determinants of PF4/heparin immunogenicity. Blood, 2007, 110, 4253-4260.	0.6	111
101	Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's witness. American Journal of Hematology, 2007, 82, 679-681.	2.0	22
102	Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2006, 355, 809-817.	13.9	560
103	Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood, 2006, 107, 2346-2353.	0.6	234
104	Lepirudin: walking the dosing line. Blood, 2006, 108, 1428-1429.	0.6	2
105	Immunoregulatory Mechanisms of PF4/Heparin Antibody Production In Vivo Blood, 2006, 108, 1050-1050.	0.6	7
106	Determinants of PF4/Heparin Immunogenicity in a Murine Model of HIT Blood, 2006, 108, 96-96.	0.6	1
107	Advantages wth Using the Levonorgestrel-Releasing Intrauterine System in Females with Hemostatic Disorders Blood, 2006, 108, 3303-3303.	0.6	0
108	PF4/heparin complexes are T cell–dependent antigens. Blood, 2005, 106, 929-931.	0.6	45

#	Article	IF	CITATIONS
109	The immune paradox of fondaparinux. Blood, 2005, 106, 3686-3687.	0.6	ο
110	Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood, 2005, 105, 131-138.	0.6	272
111	Pathogenic Role of Surface Platelet Factor 4 Complexes in Heparin-Induced Thrombocytopenia: Diagnostic and Therapeutic Implications Blood, 2005, 106, 55-55.	0.6	1
112	Dietary Hypercholesterolemia Enhances Heparin-Induced Thrombocytopenia/Thrombosis: A Prothrombotic Risk Factor in a Transgenic Mouse Model Blood, 2005, 106, 56-56.	0.6	1
113	Players in the sandbox of childhood ITP. Blood, 2004, 104, 1916-1917.	0.6	Ο
114	Heparin-Induced Thrombocytopenia Is a Thymus (T cell) Dependent Disorder Blood, 2004, 104, 3020-3020.	0.6	1
115	Characterization of Autoantibodies to PF4/Heparin in a Rat Model of Cardiopulmonary Bypass Blood, 2004, 104, 3019-3019.	0.6	0
116	Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoimmunity Reviews, 2002, 1, 125-132.	2.5	33
117	Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Annals of Thoracic Surgery, 2001, 71, 1920-1924.	0.7	34
118	Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood, 2001, 98, 1252-1254.	0.6	155
119	Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fcl³RIIA. Blood, 2001, 98, 2442-2447.	0.6	193
120	Heparin-induced thrombocytopenia and thrombosis. Clinical Reviews in Allergy and Immunology, 1998, 16, 237-247.	2.9	20
121	FcÎ ³ RIIA H/R131 Polymorphism, Subclass-Specific IgG Anti-Heparin/Platelet Factor 4 Antibodies and Clinical Course in Patients With Heparin-Induced Thrombocytopenia and Thrombosis. Blood, 1997, 89, 370-375.	0.6	122
122	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation, 1997, 95, 1242-1246.	1.6	293
123	Late Onset of Isolated Central Nervous System Metastasis of Liposarcoma—A Case Report. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 351-355.	0.6	14
124	Comparison of PF4/Heparin ELISA Assay With the ¹⁴ C-Serotonin Release Assay in the Diagnosis of Heparin-induced Thrombocytopenia. American Journal of Clinical Pathology, 1995, 104, 648-654.	0.4	206